Pharmacokinetics of 14 C-ciclesonide after oral and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
Absolute bioavailability of inhaled aclidinium bromide and safety and tolerability of aclidinium bromide administered intravenously in healthy subjects Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
Effect of oral guaifenesin (Mucinex 1200mg) on mucociliary clearance from the lungs of healthy non-smoking adults Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Pharmacokinetic characteristics of roflumilast administered in gradually increasing doses of 500μg to 1000μg are dose-linear in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
Pharmacokinetics and safety of aclidinium bromide, a novel long-acting, inhaled anticholinergic, in healthy subjects Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II Year: 2008
Salmeterol pharmacokinetics following a 50-mcg dose by dry powder oral inhalation to healthy volunteers Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Pharmacokinetics and safety of aclidinium bromide in young and elderly patients with COPD Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010
The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects after a single, oral dose of 500µg roflumilast in the morning versus evening Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Pulmonary pharmacokinetics and safety of nebulised duramycin in healthy male volunteers Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Effects of intravenous injection of TNF-a on the respiratory system of anesthetized rats Source: International Congress 2017 – Respiratory and exercise physiology Year: 2017
Urine cortisol excretion in children 4–11 years old is not affected by therapeutic doses of fluticasone propionate HFA Source: Eur Respir J 2006; 28: Suppl. 50, 260s Year: 2006
Effects on adrenal function of a new combination of fluticasone propionate/formoterol fumarate administered to asthmatic patients and healthy subjects Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 332s Year: 2006
Pharmacokinetics of roflumilast and its active metabolite roflumilast-N-oxide in middle aged and young subjects Source: Eur Respir J 2002; 20: Suppl. 38, 109s Year: 2002
Comparison of response to lipopolysaccharide administered by intravenous, orotracheal and inhaled routes in rats Source: Eur Respir J 2007; 30: Suppl. 51, 135s Year: 2007
Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients Source: Annual Congress 2009 - Cystic fibrosis: disease progression and novel therapies Year: 2009
Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019